Replimune (REPL) Cash & Equivalents (2018 - 2026)

Replimune (REPL) has 9 years of Cash & Equivalents data on file, last reported at $209.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 88.11% year-over-year to $209.0 million; the trailing twelve-month figure through Mar 2026 stood at $209.0 million (up 88.11% YoY), and the FY2026 full-year result was $209.0 million, up 88.11% from the prior year.
• Cash & Equivalents climbed to $209.0 million in Q1 2026, from $123.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $209.0 million in Q1 2026 to a low of $74.5 million in Q1 2024.
• A 5-year average of $121.4 million and a median of $111.1 million in 2025 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 95.19% in 2023, while the deepest fall reached 52.74% in 2023.
• Tracing REPL's Cash & Equivalents over 5 years: stood at $206.7 million in 2022, then tumbled by 52.74% to $97.7 million in 2023, then jumped by 76.35% to $172.2 million in 2024, then dropped by 28.62% to $123.0 million in 2025, then soared by 70.01% to $209.0 million in 2026.
• Business Quant data shows REPL's Cash & Equivalents at $209.0 million in Q1 2026, $123.0 million in Q4 2025, and $102.3 million in Q3 2025.